Advertisement

Is surgery alone sufficient for treating T1 gastric cancer with extensive lymph node metastases?

  • Masahiro Yura
  • Takaki YoshikawaEmail author
  • Sho Otsuki
  • Yukinori Yamagata
  • Shinji Morita
  • Hitoshi Katai
  • Toshirou Nishida
Original Article

Abstract

Background

Whether or not surgery alone is sufficient for treating patients with pathological stage T1N2M0 (Stage IIA), T1N3a/bM0 (Stage IIB/IIIB), and T3N0M0 (Stage IIA) gastric cancer who were not indicated for adjuvant treatment according to the Japanese gastric cancer treatment guideline remains unclear.

Methods

We retrospectively reviewed the clinical records of 236 patients who had been diagnosed with pT1N2-3b/pT3N0 gastric cancer and undergone R0 gastrectomy with lymph node dissection between January 2000 and December 2012 at the National Cancer Center Hospital, Japan.

Results

The 5-year recurrence-free survival (RFS) rates (95% confidence interval [CI]) of the patients with pathological (p) T1N2-3b and T3N0 cancer were 73.9% (63.1–84.7) and 89.5% (84.0–95.0), respectively. The only significant prognostic factors for the survival identified by a multivariate Cox regression analysis in patients with pT1N2-3 cancer were the pN stage (N3a/N2: hazard ratio [HR] 2.940, 95% CI 1.314–5.577; N3b/N2: HR 8.688, 95% CI 3.096–24.382) and tumor diameter (<30/ ≥ 30 mm) (HR 2.919; 95% CI 1.351–6.304). We divided the patients with pT1N2-3 gastric cancer into 3 risk categories (high, moderate, low) using these 2 significant prognostic factors and found that the 5-year RFS rates were significantly different among the 3 risk groups (low risk, 93.0%; moderate risk, 66.7%; high risk, 25.0%; P < 0.001).

Conclusions

pT3N0 and large pT1N2 with a diameter ≥ 30 mm had an excellent prognosis, while pT1N2-3 with at least N3a/b or a tumor diameter < 30 mm showed a relatively poor prognosis. These patients may be candidates for adjuvant chemotherapy.

Keywords

Gastric cancer T1 tumor Adjuvant chemotherapy 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interests to declare in relation to this article. This study was conducted with the approval of the National Cancer Center Hospital Ethics Committee (No: 2017-077).

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386386.  https://doi.org/10.1002/ijc.29210 (Epub 2014/09/16; PubMed PMID: 25220842).CrossRefGoogle Scholar
  2. 2.
    Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19. https://doi.org/10.1007/s10120-016-0622-4. (Epub 2016/06/28; PubMed PMID: 27342689; PubMed Central PMCID: PMCPMC5215069).
  3. 3.
    Shinichi Sakuramoto Mitsuru Sasako, Toshiharu Yamaguchi, Taira Kinoshita, Masashi Fujii, Atsushi Nashimoto, Hiroshi Furukawa, Toshifusa Nakajima, Yasuo Ohashi, Hiroshi Imamura, Masayuki Higashino, Yoshitaka Yamamura, Akira Kurita, Kuniyoshi Arai, for the ACTS-GC Group. Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine. N Engl J Med. 2007;357:1810–20.Google Scholar
  4. 4.
    Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet. 1999;354(9175):273–7.  https://doi.org/10.1016/s0140-6736(99)01048-x.CrossRefGoogle Scholar
  5. 5.
    UfIC Control. TNM classification of Malignant Tumors. 8th ed. New York: Wiley; 2017.Google Scholar
  6. 6.
    Association JGC. Japanese classification of gastric carcinoma. 15th ed. Tokyo: Kanehara Publisher; 2017.Google Scholar
  7. 7.
    Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Oro S, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192(3):296–300.  https://doi.org/10.1016/j.amjsurg.2006.03.004 (Epub 2006/08/22; PubMed PMID: 16920421)
  8. 8.
    Liu X, Xu Y, Long Z, Zhu H, Wang Y. Prognostic significance of tumor size in T3 gastric cancer. Ann Surg Oncol. 2009;16(7):1875–82.  https://doi.org/10.1245/s10434-009-0449-x (Epub 2009/04/18; PubMed PMID: 19373514) CrossRefGoogle Scholar
  9. 9.
    Aoyama T, Yoshikawa T, Fujikawa H, Hayashi T, Ogata T, Cho H, et al. Exploratory analysis to find unfavorable subset of stage II gastric cancer for which surgery alone is the standard treatment; another target for adjuvant chemotherapy. Int Surg. 2014;99(6):835–41.  https://doi.org/10.9738/INTSURG-D-13-00176.1 (Epub 2014/12/02; PubMed PMID: 25437596; PubMed Central PMCID: PMCPMC4254249).CrossRefGoogle Scholar
  10. 10.
    Wo JY, Chen K, Neville BA, Lin NU, Punglia RS. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol. 2011;29(19):2619–27.  https://doi.org/10.1200/JCO.2010.29.5907 (Epub 2011/05/25; PubMed PMID: 21606424; PubMed Central PMCID: PMCPMC3139369).CrossRefGoogle Scholar
  11. 11.
    Vinayak M, Ryan DN, David PR, Theodore SH, Paul LN, Jennifer YW. Association between very small tumor size and increased cancer-specific mortality in node-positive colon cancer. Dis Colon Rectum. 2016;59(3):187–93.Google Scholar
  12. 12.
    Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, et al. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016;118(2):279–85.  https://doi.org/10.1111/bju.13248 (Epub 2015/08/04; PubMed PMID: 26235660).CrossRefGoogle Scholar
  13. 13.
    Muralidhar V, Nipp RD, Mamon HJ, Punglia RS, Hong TS, Ferrone C, et al. Association between very small tumor size and decreased overall survival in node-positive pancreatic cancer. Ann Surg Oncol. 2018.  https://doi.org/10.1245/s10434-018-6832-8 (Epub 2018/10/10; PubMed PMID: 30298331).Google Scholar
  14. 14.
    Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017;20(2):217–25.  https://doi.org/10.1007/s10120-016-0601-9 (Epub 2016/02/22; PubMed PMID: 26897166; PubMed Central PMCID: PMCPMC4992472).CrossRefGoogle Scholar
  15. 15.
    Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27.  https://doi.org/10.1007/s10120-012-0163-4 (Epub 2012/06/26; PubMed PMID: 22729699; PubMed Central PMCID: PMCPMC3549249).CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  1. 1.Department of Gastric SurgeryNational Cancer Center HospitalTokyoJapan

Personalised recommendations